CAMBRIDGE, Mass., June 10, 2018 /PRNewswire-PRWeb/ -- CIRECA, a leader in spectroscopy-based tissue diagnostic technologies,
According to Matt Lyons, CEO of CIRECA, these studies and results mark a significant step forward in cancer research. "We are excited about the progress these studies have shown, and we realize that this marks an important time into the characterization of immune-response, although the work does not end here," he said. "We will continue to make progress on our goal to bring a greater volume of accurate cell- and tissue-based diagnostic, prognostic, and predictive decision-making information to market."
To learn more about the novel technology and advancements being made at CIRECA, please visit our website at http://www.cireca.com or email us firstname.lastname@example.org
Founded in 2011, CIRECA is the leader in IR-spectroscopy-based tissue imaging for immuno-oncology applications, to characterize the tumor microenvironment and for diagnostics. As a decision support technology, CIRECA's advanced spatial analysis and spectral-multiplex technology is applied to identify diseased cells at earlier stages of progression and to objectively measure response to therapy. The technology works by detecting biochemical signatures, and by delivering more information per sample, rapidly and at the lowest cost. CIRECA is working toward meeting future demands where more personalized and effective treatments are required to advance patient outcomes by providing new insights and discovery into tumors, microenvironments, and biomarkers.
key words/phrases: tumor, microenvironment, immunity, immune response, imaging, detection, objective measure, immuno-oncology, tissue, multiplex, multiplexing, detection
Subscribe to our Free Newsletters!